LEADER 00892nam0-22003251i-450- 001 990003264500403321 005 20100510125006.0 035 $a000326450 035 $aFED01000326450 035 $a(Aleph)000326450FED01 035 $a000326450 100 $a20030910d1975----km-y0itay50------ba 101 0 $aita 105 $ay-------001yy 200 1 $aIN UNA FABBRICA DI MOTORI$eOrganizzazione del Lavoro Potere Padronale e Lotte Operaie 205 $a1 210 $aMilano$cFeltrinelli$d1975 215 $app.272 610 0 $aRami Industriali 676 $a050.014 700 1$aBonazzi,$bGiuseppe$f<1932- >$088846 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990003264500403321 952 $a050.014.BON$b2632$fDECGE 952 $aDPR 28-413$b6046$fDEC 959 $aDECGE 959 $aDEC 996 $aIN UNA FABBRICA DI MOTORI$9451175 997 $aUNINA LEADER 04596nam 2201153z- 450 001 9910557349503321 005 20231214133008.0 035 $a(CKB)5400000000042395 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77076 035 $a(EXLCZ)995400000000042395 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aSystemic Autoinflammatory Diseases-Clinical Rheumatic Challenges 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (266 p.) 311 $a3-0365-2560-2 311 $a3-0365-2561-0 330 $aAutoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology. 606 $aMedicine$2bicssc 610 $agout 610 $afebuxostat 610 $acolchicine 610 $ahepatotoxicity 610 $aprophylaxis 610 $amyositis 610 $ainflammatory idiopathic myopathy 610 $adysphagia 610 $aaspiration 610 $apneumonia 610 $aimmunoglobulin G4-related orbital disease (IgG4-ROD) 610 $aorbital lymphoma (OL) 610 $acomputed tomography (CT) 610 $aHounsfield unit 610 $aimaging 610 $aautoinflammation 610 $aarthritis 610 $aCAPS 610 $aFCAS 610 $aMWS 610 $aCINCA 610 $aNOMID 610 $ahearing loss 610 $aurticarial-like rash 610 $aautoinflammatory disease 610 $aanti-IL-1 treatment 610 $arheumatoid arthritis 610 $asynovitis 610 $aneoplasms 610 $aedema 610 $ainflammation 610 $anew genetic variant 610 $amonogenic autoinflammatory syndrome 610 $adiagnostic delay 610 $aanakinra 610 $adamage index 610 $agenetic inheritance 610 $apersonalized therapy 610 $aInterleukin-1 610 $aautoinflammatory diseases 610 $aFMF 610 $acoronavirus 610 $aSARS-CoV-2 antibody response 610 $aadult-onset Still's disease 610 $aautoinflammatory disorder 610 $asystemic-onset juvenile idiopathic arthritis 610 $ahaemophagocytic lymphohistiocytosis 610 $amacrophage activation syndrome 610 $aIFN-? 610 $aJAK inhibitor 610 $aproliferation 610 $aDNA damage repair 610 $a?H2AX 610 $aPBMCs 610 $aT lymphocytes 610 $aproteasome 610 $aautoimmune 610 $aproteasome-associated autoinflammatory syndrome 610 $atherapy 610 $aIL-1 inhibitors 610 $aNGS 610 $aSURF 610 $aspondyloarthritis 610 $ahuman leukocyte antigen 610 $aundifferentiated enthesitis and/or arthritis 610 $aASAS classification criteria 610 $aclinical management 610 $acanakinumab 610 $acytokines 615 7$aMedicine 700 $aFeist$b Eugen$4edt$01330408 702 $aFeist$b Eugen$4oth 906 $aBOOK 912 $a9910557349503321 996 $aSystemic Autoinflammatory Diseases-Clinical Rheumatic Challenges$93039837 997 $aUNINA